CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma
Retinoblastoma
DRUG: carboplatin periocular injection|DRUG: CEV chemotherapy
Event Free Survival Rate, measure the event free survival rate for the patients at 18 months: patients that without tumor relapse or metastasis, 18 months
This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .